Key Drivers
- Strong Cash Flow
- Heavy Leverage
- Moderate Coverage
AIAI Summary
OGN should now be viewed as an event-driven merger-arbitrage name, with upside largely capped near Sun Pharma's $14 cash offer and the key trade-off shifting to whether the deal clears legal scrutiny and closes cleanly rather than to standalone turnaround upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Heavy Leverage
- •Moderate Coverage
OGN remains operationally steady and cash-generative, but its heavy leverage and only moderate interest coverage materially limit the investment case.
Price Behavior
Key Price Behavior Insights:
- •Sharp breakout
- •Tight consolidation
- •Extended rally
OGN is in a constructive uptrend over the last month, with a sharp breakout and tight consolidation near highs signaling strong momentum, though the rally looks extended and may pull back if $13.14–$13.23 fails.
Sharp jump from $8.59 to above $13.00 in late
Sentiment & News
Key News Insights:
- •Takeover premium
- •Earnings miss
- •Fairness review
Sun Pharmaceutical's all-cash $14/share takeover of Organon boosted the stock, but investor focus is now on deal fairness reviews, weaker Q1 results, and the pending close.
The acquisition is a clear near-term catalyst for OGN, but legal scrutiny and soft operating results may cap upside until the deal is finalized
Similar Companies in Healthcare
Other companies in the same sector with AI ratings